Previous close | 17.62 |
Open | 18.55 |
Bid | 15.75 x 100 |
Ask | 17.38 x 100 |
Day's range | 15.35 - 18.55 |
52-week range | 11.66 - 42.60 |
Volume | |
Avg. volume | 141,587 |
Market cap | 362.467M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Cartesian Therapeutics reported a "watershed moment" for its autoimmune-disease drug on Tuesday, but the biotech stock plunged.
Insights into Cartesian's Financial Health and Strategic Developments Amidst Expanding Clinical Trials
Cartesian Therapeutics ( NASDAQ:RNAC ) First Quarter 2024 Results Key Financial Results Revenue: US$5.84m (down 95...